Mangoceuticals
MGRX
10 hedge funds and large institutions have $444K invested in Mangoceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
202% more capital invested
Capital invested by funds: $147K → $444K (+$297K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
25% more funds holding
Funds holding: 8 → 10 (+2)
1.19% more ownership
Funds ownership: 1.46% → 2.65% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$343K |
| 2 |
Renaissance Technologies
New York
|
+$58.2K |
| 3 |
Goldman Sachs
New York
|
+$19.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$13K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$388 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$13.9K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $278K | +$343K | +182,613 | New |
|
|
ACA
2
Ackerman Capital Advisors
Dallas,
Texas
| $52.4K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $47.1K | +$58.2K | +31,000 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $40.3K | +$13K | +6,928 | +35% |
|
|
5
Goldman Sachs
New York
| $16.1K | +$19.8K | +10,570 | New |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $4.38K | – | – | – |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $3.18K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2.81K | +$388 | +207 | +13% |
|
9
Bank of America
Charlotte,
North Carolina
| $247 | +$278 | +148 | +987% |
|
|
10
UBS Group
Zurich,
Switzerland
| $120 | -$13.9K | -7,431 | -99% |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$13.8K | -7,100 | Closed |
|
MGRX Hedge Fund Activity: Q2 2025 in Review
10 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q2 2025, worth a combined $444K — up 202% from $147K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MGRX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $343K. The largest seller was UBS Group, cutting an estimated $13.9K.
- 10 institutional investors held Mangoceuticals (MGRX) as of Q2 2025, up from 8 in Q1 2025.
- Funds reported $444K of Mangoceuticals stock for Q2 2025, up 202% quarter-over-quarter.
- 3 funds opened new Mangoceuticals positions in Q2 2025 and 1 closed out, a net change of +2 holders.
- The largest Mangoceuticals buyer in Q2 2025 was Vanguard Group, an estimated $343K added.
- The largest Mangoceuticals seller in Q2 2025 was UBS Group, an estimated $13.9K sold.
Based on aggregated 13F filings for Q2 2025.